EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PLx Pharma Winddown's enterprise value is $-9.81 Mil.
PLx Pharma Winddown's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $-64.21 Mil. Therefore, PLx Pharma Winddown's EV-to-EBITDA for today is 0.15.
The historical rank and industry rank for PLx Pharma Winddown's EV-to-EBITDA or its related term are showing as below:
PLXPQ's EV-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 14.22 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
PLx Pharma Winddown EV-to-EBITDA Historical Data
The historical data trend for PLx Pharma Winddown's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PLx Pharma Winddown's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma Winddown's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PLx Pharma Winddown's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PLx Pharma Winddown's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PLx Pharma Winddown's EV-to-EBITDA falls into.
PLx Pharma Winddown's current Enterprise Value is $-9.81 Mil.
PLx Pharma Winddown's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-64.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
PLx Pharma Winddown's PE Ratio for today is calculated as:
PLx Pharma Winddown's share price for today is $0.0002.
PLx Pharma Winddown's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of PLx Pharma Winddown's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
PLx Pharma Winddown (PLx Pharma Winddown) Business Description
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PLXPQ has been successfully added to your 